| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9839631 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8212038 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(2 months from now) | |
| US9357783 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(2 months from now) | |
| US7812163 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Oct, 2026
(2 years from now) | |
| US10292389 | HATCHTECH | Pediculicidal composition |
Dec, 2034
(10 years from now) | |
Xeglyze is owned by Hatchtech.
Xeglyze contains Abametapir.
Xeglyze has a total of 5 drug patents out of which 0 drug patents have expired.
Xeglyze was authorised for market use on 24 July, 2020.
Xeglyze is available in lotion;topical dosage forms.
Xeglyze can be used as topical treatment of head lice infestation in patients 6 months of age and older.
Drug patent challenges can be filed against Xeglyze from 24 July, 2024.
The generics of Xeglyze are possible to be released after 17 December, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 24 July, 2024
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION;TOPICAL
XEGLYZE family patents
